Asset Publisher

null Grupo del Hospital Universitario Son Espases (Mallorca)

Hospital Universitario Son Espases (Mallorca)


The research group of the CORIS Hospital Son Espases-Son Llatzer Hospital is a group that has been working together since 2003, with Dr. Melchor Riera as the principal investigator. We are integrated in the Spanish AIDS Research Network (RIS), PISCIS and other European HIV research networks, we are part of the IDISBA HIV-infectious infection research group.

We use a joint platform as a clinical manager for monitoring patients with HIV infection called eVIHa that allows us to monitor daily clinical events related to HIV infection, antiretroviral treatments, against HCV, prevention, etc. These data are transferred to CORIS (currently only in the HUSE), PISCIS and other international cohorts.

In relation to HIV infection, our main lines of research are related to:

  • Lung infections, pneumococcal infection and vaccine responses to pneumococcus.
  • Tuberculosis.
  • Studies of comorbidities associated with HIV infection, mainly chronic obstructive disease-emphysema, chronic hepatitis C virus.
  • Studies of the quality of care indicators in patients with HIV infection.

As clinical researchers we have contributed to the conduct of clinical trials promoted by GESIDA, and commercial laboratories. We have also tried to collaborate in the elaboration of the assistance guides sponsored by national and international study groups.

Related Assets


Melchor Riera
Francisco Fanjul
Mercedes García
Javier Murillas
Antonio Payeras
Helem Haydee Vilchez

Related Assets

Related Assets


  • [GeSIDA quality care indicators associated with mortality and hospital admission for the care of persons infected by HIV/AIDS]. 
    Delgado-Mejía E, Frontera-Juan G, Murillas-Angoiti J, Campins-Roselló AA,Gil-Alonso L, Peñaranda-Vera M, Ribas Del Blanco MA, Martín-Pena ML, Riera-Jaume M.  Enferm Infecc Microbiol Clin. 2016 Jun 4. pii: S0213-005X(16)30109-4. doi: 10.1016/j.eimc.2016.04.012. 
  • Neuronal surface antibodies in HIV-infected patients with isolated psychosis. 
    Cunill V, Arboleya S, Jiménez ML, Campins A, Herbera P, Mestre L, Clemente A, Barceló MI, Leyes M, Canellas F, Julià MR.  J Neuroimmunol. 2016 Dec 15;301:49-52. doi: 10.1016/j.jneuroim.2016.10.008. PubMed PMID: 27836183 
  • Safe Reduction in CD4 Cell Count Monitoring in Stable, Virally Suppressed Patients With HIV Infection or HIV/Hepatitis C Virus Coinfection. 
    Nicolás D, Esteve A, Cuadros A, Campbell CN, Tural C, Podzamczer D, Murillas J, Homar F, Segura F, Force L, Vilaró J, Masabeu À, Garcia I, Mercadal J, Montoliu A, Ferrer E, Riera M, Cifuentes C, Ambrosioni J, Navarro G, Manzardo C, Clotet B, Gatell JM, Casabona J, Miró JM; PISCIS Cohort Study Investigators.  Clin Infect Dis. 2016 Jun 15;62(12):1578-85. doi: 10.1093/cid/ciw157. PubMed PMID: 27126346. 
  • GESIDA Study Group of the HIV quality indicators. [Validation and adhesion to GESIDA quality indicators in patients with HIV infection]. 
    Riera M, Esteban H, Suarez I, Palacios R, Lozano F, Blanco JR, Valencia E,Ocampo A, Amador C, Frontera G, vonWichmann-de Miguel MA;  Enferm Infecc Microbiol Clin. 2015 Oct 31. Spanish. PubMed PMID: 26530224. Factor de Impacto: 2.172.Quartile en la categoría Infectious diseases: Q3 y Microbiology: Q3. 
  • Tuberculosis in a cohort of HIV-positive patients: epidemiology, clinical practice and treatment outcomes. 
    Monge S, Diez M, Pulido F, Iribarren JA, Campins AA, Arazo P, Montero M, Miro JM, Moreno S, Del Amo J; Spanish AIDS Research Network Cohort (CoRIS).  Int J Tuberc Lung Dis. 2014 Jun;18(6):700-8. Factor de impacto:2.315. Quartile en la categoría: Infectious Diseases: Q3 and Respiratory System: Q3. 
  • Prevalence of and risk factors for pulmonary abnormalities in HIV-infected patients treated with antiretroviral therapy. 
    Sampériz G, Guerrero D, López M, Valera J, Iglesias A, Ríos A, Campins A, Sala, E, Murillas J, Togores B, Palmer J, Rodriguez M, Soriano J, Sauleda J, Riera M, Agusti A.  HIV Med. 2014 Jul;15(6):321-9. Factor de impacto: 3.988. Quartile en la categoría: Infectious Diseases: Q1 
  • PISCIS Investigators. Optimal timing for initiation of highly active antiretroviral therapy in treatment-naïve human immunodeficiency virus-1-infected individuals presenting with AIDS-defining diseases: the experience of the PISCIS Cohort. 
    Manzardo C, Esteve A, Ortega N, Podzamczer D, Murillas J, Segura F, Force L, Tural C, Vilaró J, Masabeu A, Garcia I, Guadarrama M, Ferrer E, Riera M, Navarro G, Clotet B, Gatell JM, Casabona J, Miró JM;  Clin Microbiol Infect. 2013 Jul;19(7):646-53. Factor de Impacto: 5.197 
  • Evaluation of progressive multifocal leukoencephalopathy treatments in a Spanish cohort of HIV-infected patients: do protease inhibitors improve survival regardless of central nervous system penetration-effectiveness (CPE) score? 
    Fanjul F, Riveiro-Barciela M, González J, Delgado E, Murillas J, Payeras CifreA, Falcó V, Riera M.  HIV Med. 2013 May;14(5):321-5. Factor de impacto: 3.454. 
  • Invasive pneumococcal disease in HIV-infected adults: clinical changes after the introduction of the pneumococcal conjugate vaccine in children. 
    Burgos J, Peñaranda M, Payeras A, Villoslada A, Curran A, Garau M, Riera M,Crespo M, Navarro J, Van den Eynde E, Planes AM, Ribera E, Pahissa A, Falcó V.  J Acquir Immune Defic Syndr. 2012 Jan 1;59(1):31-8. Factor de Impacto: 4.653. 
  • Pharmacogenetics of efficacy and safety of HCV treatment in HCV-HIV-coinfected patients: significant associations with IL28B and SOCS3 gene variants. 
    Vidal F, López-Dupla M, Laguno M, Veloso S, Mallolas J, Murillas J, Cifuentes C, Gallart L, Auguet T, Sampériz G, Payeras A, Hernandez P, Arnedo M, Gatell JM, Richart C.  PLoS One. 2012;7(11):e47725. Factor de Impacto: 3.730. 

Related Assets